Three cents on the dollar

In mid-October, China proposed export controls that would restrict the outright transfer of key technologies, including siRNA and cell-and-gene-therapy platforms, while leaving licensing exempt. In plain terms, the drug could still leave, but the platform would have to stay. The proposal is in a comment period, so this is where things stand today, not a settled rule.

The licensing math is already striking. By one industry tally, a single recent week saw about five China-originated licensing deals with roughly $21 billion in headline value but under about $0.7 billion in combined upfront, close to three cents of the headline paid at signing. China assets have been reported at around 58 percent of global licensing value but only about 1 percent of M&A value. The pattern is a flood of contingent headlines and very little committed cash.

If the proposed fences hold, they push value in a clear direction. Restricting the transfer of platforms makes Western-owned, de-risked assets scarcer and therefore more valuable to buyers who want to own, not just license. For the owners we represent, that scarcity is leverage, and it reinforces the point we make in every process: the upfront, the cash committed at closing, is where the real deal lives.

Nothing here is investment advice, and this note is not an endorsement of any transaction described. Figures are as publicly reported.

Work with Modulus

Filling a pipeline gap?

Talk to us →

Have a program worth de-risking?

See how we work with inventors →